Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Nurix Therapeutics's ebitda for the twelve months ending Aug 31, 2026 was $298.37M. For fiscal 2025 it was -$276.93M. The highest annual figure on record is -$19.88M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$276.93M | – |
| FY2024 | Nov 30, 2024 | -$203.71M | – |
| FY2023 | Nov 30, 2023 | -$147.53M | – |
| FY2022 | Nov 30, 2022 | -$178.52M | – |
| FY2021 | Nov 30, 2021 | -$115.10M | – |
| FY2020 | Nov 30, 2020 | -$62.80M | – |
| FY2019 | Nov 30, 2019 | -$19.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $561.59M | – |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -$91.95M | – |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -$90.30M | – |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$80.98M | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -$89.36M | – |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -$46.08M | – |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -$60.51M | – |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$62.11M | – |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -$52.22M | – |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -$46.21M | – |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -$43.17M | – |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -$43.40M | – |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -$38.06M | – |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -$24.87M | – |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -$41.20M | – |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -$47.07M | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -$45.22M | – |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -$44.42M | – |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -$41.75M | – |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$37.20M | – |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -$28.30M | – |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -$25.81M | – |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | -$23.88M | – |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -$19.36M | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -$18.59M | – |
| Q2 FY2020CQ2 2020 | May 31, 2020 | -$12.73M | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | -$12.06M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -$13.02M | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | -$2.01M | – |
See a number that looks wrong?